ReviewProtein & cell2021
Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.
Review in Protein & cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 87 citations in OpenAlex.
- The Gut-Adipose-Tumor Axis in Obesity-Related Cancer.Nutrients · 2026Review
- The Causal Role of Bile Acids in Cancers of the Digestive System.Biomedicines · 2026Review
- Inhibition of PFKFB3 in macrophages ameliorates intestinal inflammation by modulating gut microbiota in DSS-induced colitis.mSystems · 2026Article
- Comparative effects of periodontitis - versus periodontal health-derived saliva on systemic lipid metabolism in mice: mediation through oral-gut axis.Journal of oral microbiology · 2026Article
- The Dual Role of Gut Microbiota and Their Metabolites in Hepatocellular Carcinoma: A Context-Dependent Framework.Microorganisms · 2025Review
- Cdk5 regulates glutamine metabolism in colorectal cancer via the EZH2-GLS1 axis.Cancer & metabolism · 2025Article
- The Potential Role of Microalgal Antioxidant Molecules on the Microbiota-Gut Axis in Inflammatory Bowel Diseases.Biomolecules · 2025Review
- Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Review
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer.mSystems · 2025Article
- Gut microbial characteristics of the damp-heat constitution: a population-based multicenter cross-sectional study.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- The microbiological and metabolic traits associated with pT3 colorectal cancer metastasis to lymph nodes.Frontiers in physiology · 2025Article
- Akkermansia muciniphila Mediated the Preventive Effect of Disulfiram on Acute Liver Injury via PI3K/Akt Pathway.Microbial biotechnology · 2025Article
- Quercetin boosts gut microbiota-driven production of isovanillic acid to alleviate colitis via enhancing intestinal barrier function.Current research in food science · 2025Article
- Gut Microbiota and the Gut-liver Axis in Hepatocellular Carcinoma: A Comprehensive Review of Pathogenesis and Therapeutic Strategies.Anti-cancer agents in medicinal chemistry · 2025Review
- Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights.Frontiers in cellular and infection microbiology · 2025Review
- Liver Cancer Etiology: Old Issues and New Perspectives.Current oncology reports · 2024Review
- Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.mSystems · 2024Article
- A comparative analysis of mutual information methods for pairwise relationship detection in metagenomic data.BMC bioinformatics · 2024Article
- Recent developments in immunotherapy for gastrointestinal tract cancers.Journal of hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
Colorectal cancer (CRC) and hepatocellular carcinoma (HCC) are the second and third most common causes of death by cancer, respectively. The etiologies of the two cancers are either infectious insult or due to chronic use of alcohol, smoking, diet, obesity and diabetes. Pathological changes in the composition of the gut microbiota that lead to intestinal inflammation are a common factor for both HCC and CRC. However, the gut microbiota of the cancer patient evolves with disease pathogenesis in unique ways that are affected by etiologies and environmental factors. In this review, we examine the changes that occur in the composition of the gut microbiota across the stages of the HCC and CRC. Based on the idea that the gut microbiota are an additional "lifeline" and contribute to the tumor microenvironment, we can observe from previously published literature how the microbiota can cause a shift in the balance from normal → inflammation → diminished inflammation from early to later disease stages. This pattern leads to the hypothesis that tumor survival depends on a less pro-inflammatory tumor microenvironment. The differences observed in the gut microbiota composition between different disease etiologies as well as between HCC and CRC suggest that the tumor microenvironment is unique for each case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.